MarketCap
Facebook
X
Telegram
AVEO Pharmaceuticals DPO Ratio | AVEO
Annual DPO Ratio AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 547 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 547 | 547 | 547 |
Quarterly DPO Ratio AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 99.5 | 98.5 | 107 | 171 | 212 | 395 | 2.43 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.43 K | 98.5 | 502 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M |  USA |
 |
Zosano Pharma Corporation
ZSAN
|
918 | - | 7.23 % | $ 2.72 M | USA |
 |
Oncternal Therapeutics
ONCT
|
422 | - | -24.12 % | $ 1.56 M | USA |
 |
Spectrum Pharmaceuticals
SPPI
|
1.05 K | - | - | $ 189 M | USA |
 |
ImmunoGen
IMGN
|
31.7 | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
2.32 K | - | -8.77 % | $ 12.4 M |  Israel |
 |
Histogen
HSTO
|
203 | - | 31.6 % | $ 2.12 M | USA |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Clovis Oncology
CLVS
|
236 | - | -7.23 % | $ 13 M | USA |
 |
VBI Vaccines
VBIV
|
96.8 | - | -50.87 % | $ 1.09 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
306 | - | - | $ 1.2 B | USA |
 |
Reata Pharmaceuticals
RETA
|
5.6 | - | - | $ 6.29 B | USA |
 |
PolarityTE
PTE
|
187 | - | -0.82 % | $ 1.78 M | USA |
 |
Trevena
TRVN
|
511 | - | -46.58 % | $ 31.8 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
155 | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
333 K | - | -2.99 % | $ 2.47 M | USA |
 |
InMed Pharmaceuticals
INM
|
18 | $ 14.77 | 13.57 % | $ 61.5 M |  Canada |
 |
SpringWorks Therapeutics
SWTX
|
286 | - | - | $ 3.48 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
1.05 K | - | -46.98 % | $ 3.57 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | Israel |